Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) CEO Purchases $59,500.00 in Stock

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) CEO Seth Lederman acquired 25,000 shares of the firm’s stock in a transaction dated Tuesday, March 26th. The shares were acquired at an average price of $2.38 per share, for a total transaction of $59,500.00. Following the acquisition, the chief executive officer now directly owns 1,767 shares of the company’s stock, valued at $4,205.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Seth Lederman also recently made the following trade(s):

  • On Friday, March 29th, Seth Lederman bought 5,000 shares of Tonix Pharmaceuticals stock. The stock was purchased at an average cost of $2.49 per share, for a total transaction of $12,450.00.

Shares of TNXP traded down $0.05 during trading hours on Friday, hitting $2.38. The stock had a trading volume of 386,678 shares, compared to its average volume of 1,153,929. Tonix Pharmaceuticals Holding Corp has a 12-month low of $1.70 and a 12-month high of $51.10. The firm has a market capitalization of $14.49 million, a P/E ratio of -0.09 and a beta of 1.91.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Monday, March 18th. The company reported ($6.10) EPS for the quarter, missing the consensus estimate of ($3.66) by ($2.44). On average, equities research analysts forecast that Tonix Pharmaceuticals Holding Corp will post -3.97 EPS for the current year.

Separately, Roth Capital raised Tonix Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Thursday.

Several hedge funds and other institutional investors have recently made changes to their positions in TNXP. Bank of New York Mellon Corp purchased a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth about $38,000. Citigroup Inc. purchased a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth about $34,000. Finally, CVI Holdings LLC purchased a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth about $36,000. 8.58% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) CEO Purchases $59,500.00 in Stock” was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/seth-lederman-buys-25000-shares-of-tonix-pharmaceuticals-holding-corp-tnxp-stock.html.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population.

See Also: Balance Sheet

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.